Articles On Actinogen Medical (ASX:ACW)

Alzheimer’s disease research is burgeoning – and Actinogen Medical is one of the most advanced players EBR Systems’ limited US rollout approach was a Wise move Amid increased sales, Neuren Pharmaceuticals mulls a franked dividend   No few...

Sleep apnoea giant Resmed splurges $US360 million ($500m) to buy a company tackling restless leg syndrome April was the cruellest month for ASX biotechs Arovella coup claims more scalps   Having conquered sleep apnoea (snoring), ResMed (...

Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ASX healthcare names now in the high-stak...

 Syntara is getting its myelofibrosis program back on track after last year’s setback All the latest news on the quarterly reporting fiesta Dimerix’s trial tweak is a case of trading off time versus risk   The developer of a drug for the...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin An additional news report on the recommendation, valuation, forecast and opinion cha...

A gaggle of drug developers is due to disclose company-making clinical study results this year While late-stage clinical trial victory does not confer commercial success, the results tend to be ‘do or die’ In the main, share valuations don...

ASX recovers from -0.54% session low to lift 0.07% Blue-chip stocks weigh heavy despite positive breadth Iranian ceasefire under threat as situation deteriorates in Strait of Hormuz US seizes Iranian vessel in Strait of Hormuz The Strait...

Following the clinical trial setbacks from drug developers Opthea, Immutep, Percheron and Argenica Therapeutics, the local sector could really do with a win. Actinogen Medical (ASX:ACW) could be the one to pull the sector out of its funk –...

Ageing is quietly becoming a massive healthcare opportunity From stroke to lungs to memory, the cracks are showing LTR Pharma taps into the part no one talks about   Australians are getting older, but this isn’t a generation easing into q...

Morgans healthcare analyst Iain Wilkie highlights seven ASX companies with upcoming catalysts  Dimerix moving into major catalyst window as investors look for further updates from Phase III trial of DMX-200 in FSGS Cynata has results of tw...

The Ides of March weighed down the sector, but green shoots of recovery may make April fools of the naysayers Telix Pharmaceuticals shares led the top end recovery with a 40% gain It’s April – and drug developers with names starting with ‘...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

Actinogen’s pivotal Alzheimer’s trial has passed a crucial ‘futility’ analysis The company is raising up to $15 million to further its drug candidate, Xanamem Xanamem targets a different mechanism of action to other failed Alzheimer’s drug...

The ASX 200 was up almost 2% in January, pushed higher by strong gains in the energy and materials sectors  Not all good news, with higher inflation increasing the odds of a February rate rise, and Bitcoin falling ~10% for the month Apollo...

The Perth drug developer is raising big bucks to fund four clinical programs to fruition Deals! Deals! Deals! Aussie biotechs show the world is their oyster LTR Pharma says its erectile dysfunction drug works with younger patients While...

ASX reverses fortunes, falling from +0.49% to -0.65% Metal prices crash out; materials sector and gold index plunge Defence stocks fall out of favour   Commodities go down in flames Another instance of ‘what goes up must come down’, broug...

ASX recovers from session lows of -0.84% to dip just -0.07% Info Tech extends losses, falling to Feb 2024 levels Uranium and gold stocks fuel materials and energy gains   Tech in harsh retreat The struggling info tech sector took another...

Will Actinogen’s Xanamia trial prove a bigger hit than ABBA, or is it the company’s Waterloo? Upbeat Mach 7 licks its wounds after contract loss Neurizon and Heramed go to the well Alzheimer’s disease drug hopeful Actinogen Medical (ASX:A...

ASX up 0.56% or 49.1 points with solid breadth (122/200 stocks rising) Materials, banks provide momentum while energy retreats Seven of 11 sectors in the red, but solid support from Resources and Banks indices   Market climbs metals ladde...

ASX 200 dips three points, or 0.03% Even split with six sectors in the red Info tech, banks and materials weigh heavy as energy recovers   Market crabwalks through first full week On the whole, the ASX 200 traded mostly sideways in the fi...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin An additional news report on the recommendation, valuation, forecast and opinion cha...

In a tight race, drug developer Nyrada so far is this year’s star performer with almost an eightfold gain Diagnostic house Lumos and imagers Artrya and 4D Medical also have run a good race, with their US plans unfolding to script Nyrada ch...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

A global study links Alzheimer’s disease with kidney malfunction FDA czar Dr Marty Makary outlines the agency’s priorities Pro Medicus fesses up to a cyber breach   The quest for an Alzheimer’s disease cure has taken a new twist, with an...

The ASX 200 fell 2.66% in November, with the tech sector dumping almost 12% Concerns about an AI-fuelled market bubble weighed on global sentiment as Aussie inflation came in hotter-than-expected Mount Ridley Mines continued its stellar ru...

Highlights Broad uptrend momentum seen across diverse sectors. Multiple companies experience renewed chart strength. Downtrend signals highlight shifting market sentiment. A comprehensive exploration of rising and weak...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

If you’ve been a consistent reader of Fat Tail Daily or our paid subscription services, you’ve likely done well from the recent critical minerals and rare earth rally. It’s been one of the few themes all Fat Tail Editors have firmly agreed...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Phase 2b/3 Alzheimer’s trial enrolment passes 50% – twenty US trial sites continu...

Neuren’s US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs “with immediate effect”   Despite firming US sales of its Re...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Eye drug developer Opthea’s cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today’s sector gains after a US deal with a mystery party    The...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studyi...

Neurizon Therapeutics (ASX:NUZ) has this week arrived at its next “watershed moment” as it looks to become a leader in neurodegenerative disease treatments, executing a global license agreement with Elanco Animal Health Inc. Listen to th...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Marmota Limited (ASX:MEU) will be starting its first-ever drilling at Greenewood within the next week, with the maiden run – which will double the holes at the project – coming just days after the explorer confirmed the title transfer. L...

In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s “safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time. Listen to the Hot...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Interim analysis planned for January 2026 with final trial results in late 2026 H...

Actinogen Medical (ASX:ACW) has this week enrolled its 100th participant for its “pivotal” XanaMIA phase 2b/three trial for Xanamem, its investigational drug designed to treat the cognitive decline in Alzheimer’s disease. Listen to the H...

Highlights BVF Partners exits Syntara citing fund size constraints, not program performance Trial data for myelofibrosis drug candidate shows continued progress Syntara to discuss future clinical development path with US FDA...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

There are several ASX biotech companies developing drugs to treat complex neurological conditions Global neurological disorder drugs market size set to reach US$149.17 billion by 2032 Petra Capital’s Tanushree Jain says neurological disord...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...